Inhibition of glycogen synthase kinase-3β prevents NSAID-induced acute kidney injury  by Bao, Hao et al.
Inhibition of glycogen synthase kinase-3b prevents
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Clinical use of nonsteroidal anti-inflammatory drugs (NSAIDs)
like diclofenac (DCLF) is limited by multiple adverse effects,
including renal toxicity leading to acute kidney injury.
In mice with DCLF-induced nephrotoxicity, TDZD-8,
a selective glycogen synthase kinase (GSK)3b inhibitor,
improved acute kidney dysfunction and ameliorated tubular
necrosis and apoptosis associated with induced cortical
expression of cyclooxygenase-2 (COX-2) and prostaglandin E2.
This renoprotective effect was blunted but still largely
preserved in COX-2-null mice, suggesting that other GSK3b
targets beyond COX-2 functioned in renal protection.
Indeed, TDZD-8 diminished the mitochondrial permeability
transition in DCLF-injured kidneys. In vitro, GSK3b inhibition
reinstated viability and suppressed necrosis and apoptosis
in DCLF-stimulated tubular epithelial cells. DCLF elicited
oxidative stress, enhanced the activity of the redox-sensitive
GSK3b, and promoted a mitochondrial permeability
transition by interacting with cyclophilin D, a key component
of the mitochondrial permeability transition pore. TDZD-8
blocked GSK3b activity and prevented GSK3b-mediated
cyclophilin D phosphorylation and the ensuing mitochondrial
permeability transition, concomitant with normalization
of intracellular ATP. Conversely, ectopic expression of a
constitutively active GSK3b abolished the effects of TDZD-8.
Hence, inhibition of GSK3b ameliorates NSAID-induced acute
kidney injury by induction of renal cortical COX-2 and direct
inhibition of the mitochondrial permeability transition.
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Diclofenac (2-[(2,6-dichlorophenyl)amino]phenyl-acetate,
DCLF) is one of the most frequently prescribed nonsteroidal
anti-inflammatory drugs (NSAIDs). Its clinical use is limited
by the occurrence of DCLF-induced renal toxicity, which
can manifest as acute kidney injury (AKI).1,2 Acute DCLF-
induced nephrotoxicity involves both cyclooxygenase (COX)-
dependent and COX-independent mechanisms. The blocking
of COX and subsequent inhibition of prostaglandin (PG)
synthesis by DCLF leads to renovascular constriction, renal
ischemia, a decline in glomerular hydraulic pressure, and
AKI. Moreover, recent evidence suggests that mitochondria
are a primary target of DCLF.3–5 DCLF can directly induce
the mitochondrial membrane permeability transition (MPT),
which subsequently triggers cell death in multiple organs,
including the kidneys.6–8
Glycogen synthase kinase-3b (GSK3b) is a ubiquitous
serine–threonine protein kinase that participates in a multi-
tude of cellular processes, including proliferation, apoptosis,
and necrosis, and has an important role in the pathophysi-
ology of a number of diseases, including kidney diseases.
Previous studies have demonstrated that GSK3b inhibition
induces COX-2 expression in the renal cortex.9,10 In addition,
a growing body of evidence suggests that GSK3b inhibition
has a central role in both the ischemic and pharmacological
preconditioning–induced modulation of MPT induction.11,12
Inhibitory phosphorylation of GSK3b at serine 9 resulted in
an elevated threshold for MPT activation and, consequently,
protected from cell death.
In this study, we examined the effects of 4-benzyl-2-methyl-
1,2,4-thiadiazolidine-3,5-dione (TDZD-8), a novel, non-ATP
competitive, highly selective small-molecule inhibitor of GSK3b,
on the development of DCLF-induced acute nephrotoxicity
in vivo in a murine model of DCLF-induced nephrotoxicity
and in vitro in cultured renal proximal tubular cells.
RESULTS
GSK3b inhibition improves general behavior and kidney
function in DCLF-injured mice
Mice were pretreated with TDZD-8 or vehicle 1 h before
injury by a nephrotoxic dose of DCLF (200mg/kg) via oral
gavages. After 6 h, illness and weakness became evident in the
animals that received DCLF and vehicle alone. They were
lethargic and reluctant to eat. Kidneys from DCLF-treated
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mice appeared enlarged and swollen, and markedly higher
serum creatinine levels were detected in these mice, denoting
acute kidney dysfunction (Table 1). In contrast, treatment
with TDZD-8 significantly improved animal activity and
food intake, attenuated weight loss, and preserved renal
function in DCLF-injured mice.
GSK3b inhibition prevents tubular necrosis and apoptosis in
the kidneys of DCLF-injured mice
As shown in Figure 1, exposure to DCLF induced a typical
pattern of acute tubular necrosis in the proximal and distal
tubules, which was characterized by isometric vacuolization
of the tubular epithelium, luminal ectasia, sloughing of
tubular cells into the lumen, loss of brush border, nuclear
enlargement, and pleomorphism. To visualize apoptosis,
TdT-mediated dUTP nick-end labeling (TUNEL) staining
was performed (Figure 1b, d, f, h, and j). Scattered, bright
TUNEL-positive nuclei could be evidently observed over the
entire cortex of the DCLF-injured kidneys, but were rarely
observed in the specimens from control mice. Both tubular
necrosis and apoptosis were significantly attenuated in
TDZD-8-treated mice.
Table 1 | Changes in body weight, kidney weight, and serum creatinine (SCr) levels after different treatments
Group Ctrl T D TL+D T+D
Base weight (g) 19.1±1.0 19.8±0.8 19.8±0.9 19.6±0.7 19.3±0.6
Weight change (g) 0.01±0.16 0.07±0.09 1.44±0.20* 0.85±0.10** 0.55±0.12**
Kidney weight (mg) 127.0±3.6 124.6±3.3 176.4±9.9* 158.7±6.8** 148.0±3.5**
SCr (mg/dl) 0.19±0.03 0.21±0.02 1.36±0.16* 0.98±0.20** 0.67±0.10**
Abbreviations: Group Ctrl, control mice treated with vehicle; Group D, 2-[(2,6-dichlorophenyl)amino]phenyl-acetate (DCLF; 200mg/kg)-injured mice; Group T, 4-benzyl-2-
methyl-1,2,4-thiadiazolidine-3,5-dione (TDZD-8; 5mg/kg)-treated mice; Group TL+D, low-dose TDZD-8 (1mg/kg) + DCLF (200mg/kg)-treated mice; Group T+D, TDZD-8
(5mg/kg) + DCLF (200mg/kg)-treated mice.
*Po0.05 vs. group Ctrl.
**Po0.05 vs. group D.
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Figure 1 |Glycogen synthase kinase-3b (GSK3b) inhibition protects mice from 2-[(2,6-dichlorophenyl)amino]phenyl-acetate (DCLF)-
induced renal tubular injury and cell apoptosis in vivo. Representative micrographs of hematoxylin and eosin (HE) staining (a, c, e, g, i)
and TdT-mediated dUTP nick-end labeling (TUNEL) staining (b, d, f, h, j) of kidney specimens. (a, b) Group Ctrl, control (vehicle treated); (c,
d) Group T, 4-benzyl-2-methyl-1,2,4-thiadiazolidine-3,5-dione (TDZD-8; 5mg/kg); (e, f) Group D, DCLF (200mg/kg); (g, h) Group TLþD,
low-dose TDZD-8 (1mg/kg)þDCLF (200mg/kg); (i, j) Group TþD, TDZD-8 (5mg/kg)þDCLF (200mg/kg). (k, l) Quantitative analysis
of tubular injury and TUNEL-labeled cells among the groups. The results are expressed as the mean±s.d. (n¼ 6). *Po0.05 vs. Group Ctrl;
#Po0.05 vs. Group D. DCLF-elicited injury to both proximal and distal tubular cells. TUNEL-labeled nuclei were revealed as bright spots
in the renal cortex in kidneys from DCLF-treated mice. TDZD-8 significantly attenuated both tubular necrosis and apoptosis in mouse
kidneys.
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TDZD-8 inhibits GSK3b activity and induces cortical COX-2
in DCLF-injured kidneys
In DCLF-injured kidneys, enhanced GSK3b activity was
demonstrated by reduced inhibitory phosphorylation of
GSK3b at serine 9. TDZD-8, a highly selective small-molecule
inhibitor of GSK3b, induced prominent phosphorylation of
GSK3b in both control and DCLF-injured kidneys, denoting
the inhibition of GSK3b kinase activity (Figure 2a). One
important mechanism of NSAID-induced kidney injury is
the inhibition of COX activity in the kidney. Indeed, PGE2
levels in the renal cortices were significantly decreased in
DCLF-injured kidneys (Figure 2c). The compensatory
induction of renal cortical COX-2 was observed in DCLF-
injured mice, and this was augmented following TDZD-8
treatment (Figure 2b). This is consistent with previous
reports in other animal models that GSK3b inhibition
induces COX-2 expression.9,10 The decreased PGE2 levels
in the renal cortex were partially abrogated after TDZD-8
treatment (Figure 2c).
Renal protective effects of GSK3b inhibition on DCLF-induced
AKI is largely preserved in COX-2-null mice
To determine whether the beneficial effects of GSK3b inhi-
bition were entirely mediated by the induction of COX-2
expression, the COX-2-knockout mice were administered a
nephrotoxic dose of DCLF following pretreatment with either
TDZD-8 or vehicle. As shown in Figure 3, the renoprotective
efficacy of TDZD-8 was slightly but significantly blunted in
the COX-2-null mice, as evidenced by the difference in the
tubular injury scores, as well as in the serum creatinine levels
(Figure 3b and c) between the wild-type and the knockout
mice injured with DCLF and treated with TDZD-8,
suggesting that COX-2 is involved in the mechanism of
kidney protection. However, TDZD-8 could still effectively
ameliorate the DCLF-induced AKI and acute tubular necrosis
in COX-2-null mice, and the renoprotective effect of
TDZD-8 was actually largely preserved in COX-2-null mice,
indicating that a COX-2/PGE2-independent pathway also
contributes, at least in part, to kidney protection.
GSK3b inhibition suppresses MPT in DCLF-injured kidneys
Both persistent ischemia and direct DCLF toxicity can induce
MPT, a critical mechanism causing cell death. Whether
TDZD-8 protects kidneys from DCLF-induced MPT was
studied next. In isolated mitochondria, the capacity to
tolerate a calcium challenge is inversely correlated with the
susceptibility to the MPT. To assess the MPT in vivo, renal
mitochondria were purified, and calcium-induced mitochon-
drial swelling was measured as a decrease in spectrophoto-
metric absorbance at 540 nm. As can be seen in Figure 4,
mitochondria isolated from the kidneys of DCLF-treated
mice displayed a greater decrease in absorbance at 540 nm
upon calcium overload, denoting an accelerated rate of
mitochondrial swelling and marked mitochondrial dysfunc-
tion. TDZD-8 treatment significantly ameliorated this effect
in a dose-dependent manner (Figure 4). More importantly,
the extent of calcium-induced mitochondrial swelling was
negatively correlated with both the number of apoptotic cells
in the kidneys and the severity of renal histological injury.
These findings suggest that TDZD-8 protected renal cells
from apoptosis and necrosis primarily by inhibiting MPT
in vivo.
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Figure 2 | Effects of 4-benzyl-2-methyl-1,2,4-thiadiazolidine-3,5-dione (TDZD-8) on glycogen synthase kinase-3b (GSK3b)
phosphorylation and the levels of cyclooxygenase-2 (COX-2) and prostaglandin E2 (PGE2) in kidney cortices of 2-[(2,6-dichloro-
phenyl)amino]phenyl-acetate (DCLF)-treated mice. (a) Western blot analysis of GSK3b and p-GSK3b in cortical homogenate. (b) Western
blot analysis of COX-1 and COX-2 in cortical homogenate. (c) Analysis of cortical PGE2 in cortical homogenate. Group Ctrl, control (vehicle
treated); Group T, TDZD-8 (5mg/kg); Group D, DCLF (200mg/kg); Group TLþD, TDZD-8 (1mg/kg)þDCLF (200mg/kg); Group TþD,
TDZD-8 (5mg/kg)þDCLF (200mg/kg). *Po0.05 vs. Group Ctrl; #Po0.05 vs. Group D. COX-1 expression was maintained and COX-2
expression was increased following treatment with DCLF. GSK3b inhibition led to a further increase in COX-2 expression in the renal cortices
of DCLF-treated mice. Accordingly, PGE2 synthesis was increased in TDZD-8-treated mice.
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GSK3b inhibition improves the cell viability of renal tubular
epithelial cells exposed to DCLF
To determine whether treatment with TDZD-8 ameliorated
DCLF-induced AKI via a direct protective effect on renal
tubular cells, cultured murine tubular epithelial (TKPT) cells
were exposed to DCLF at different doses for different
intervals in the presence or absence of TDZD-8. DCLF
stimulation reduced cellular viability in a dose-dependent
(Figure 5a) and time-dependent (Figure 5b) manner, as
assessed by tetrazolium (MTT) assays, and this effect could
be significantly counteracted by treatment with TDZD-8
(Figure 5c). In contrast, in cells expressing S9A-GSK3b—an
uninhibitable mutant of GSK3b in which serine 9 was
replaced by alanine—the protective activity of TDZD-8 was
blunted (Figure 5d), suggesting that the inhibitory phos-
phorylation of GSK3b is required for the protective effect of
TDZD-8.
GSK3b inhibition protects from DCLF-induced apoptosis and
necrosis in renal tubular epithelial cells
As shown in Figure 6, DCLF induced significant cell apop-
tosis within 24 h. Treatment with TDZD-8 significantly
decreased the number of apoptotic cells, as detected by
TUNEL staining, and the anti-apoptotic effect of TDZD-8
was attenuated in cells expressing S9A-GSK3b, indicating the
indispensable role of phosphorylation in the inhibition of
GSK3b. To assess necrosis, we undertook both a morpho-
logical examination of propidium iodide staining of cultured
cells (Figure 7a and b) and a biochemical assay for the
enzymatic activity of cytoplasmic lactate dehydrogenase
(Figure 7c), which is released into conditioned media upon
cellular necrosis and rupture of the plasma membrane. DCLF
stimulation augmented both lactate dehydrogenase activity
and propidium iodide positivity, and this was substantially
reduced by treatment with TDZD-8. In cells expressing the
S9A-GSK3b mutant, the antinecrotic effect of TDZD-8 was
similarly blunted, suggesting that inhibitory phosphory-
lation of GSK3b is essential for the protection of the cells by
TDZD-8.
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Figure 3 |Glycogen synthase kinase-3b (GSK3b) inhibition
protects cyclooxygenase-2 (COX-2/) mice from 2-[(2,6-
dichlorophenyl)amino]phenyl-acetate (DCLF)-induced renal
tubular injury. (a) mRNA expression of COX-2 detected by
reverse transcription-PCR (RT-PCR) in the kidneys of wild-type
(WT) and COX-2-knockout (KO) mice. (b) Tubular injury score of
WT and COX-2 KO mice treated with DCLF (200mg/kg) and/or
4-benzyl-2-methyl-1,2,4-thiadiazolidine-3,5-dione (TDZD-8;
5mg/kg). (c) Serum creatinine (SCr) of WT and COX-2 KO mice
treated with DCLF (200mg/kg) and/or TDZD-8 (5mg/kg).
(d) Representative micrographs of hematoxylin and eosin staining
of kidney specimens from COX-2 KO mice treated with DCLF
(200mg/kg) and/or TDZD-8 (5mg/kg). Ctrl, control (vehicle
treated). *Po0.05 vs. control; #Po0.05 vs. DCLF-treated mice.
DCLF produced injury to both proximal and distal tubular cells.
This kidney-protective effect of TDZD-8 was blunted but still
largely preserved in COX-2-null mice.
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Figure 4 | Effects of glycogen synthase kinase-3b
(GSK3b) inhibition on the induction of the mitochondrial
membrane permeability transition (MPT) by 2-[(2,6-dichloro-
phenyl)amino]phenyl-acetate (DCLF) in mouse kidneys.
(a) Mitochondrial swelling was spectrophotometrically monitored
at 540 nm following induction with 20 mM CaCl2 for 20min.
(b) Change in absorbance at optical density (OD) 540 nm
after 20min. (c) Correlation between decreased absorbance
at 540 nm and the renal tubular injury score. (d) Correlation
between decreased absorbance at 540 nm and the number
of apoptotic cells in renal tissues. Group Ctrl, control (vehicle
treated); Group T, 4-benzyl-2-methyl-1,2,4-thiadiazolidine-3,
5-dione (TDZD-8; 5mg/kg); Group D, DCLF (200mg/kg);
Group TLþD, TDZD-8 (1mg/kg)þDCLF (200mg/kg); Group
TþD, TDZD-8 (5mg/kg)þDCLF (200mg/kg). *Po0.05 vs.
Group Ctrl; #Po0.05 vs. Group D. The decrease in absorbance
at 540 nm was negatively correlated with the number of apoptotic
cells and the renal tubular injury scores in mouse kidneys.
Mitochondria that were isolated from kidneys treated with
DCLF displayed an increased rate of mitochondrial swelling and
a greater decrease in absorbance at 540 nm vs. the controls,
whereas TDZD-8 treatment ameliorated this process in a
dose-dependent manner.
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GSK3b inhibition attenuates DCLF-induced MPT in renal
tubular epithelial cells
The mitochondrial dye tetramethylrhodamine methyl ester
(TMRM) was used to monitor the onset of the MPT in
cultured TKPT cells. Under basal conditions, the lipophilic
TMRM, which bears a delocalized positive charge, enters
the negatively charged mitochondria and accumulates in a
potential-dependent manner along the inner membrane
(Figure 8a). Upon MPT, the MPT pore opens, and the
TMRM potentiometric dye no longer accumulates inside
the mitochondria, but is instead distributed throughout the
cytosol. In our study, following DCLF stimulation, the
overall cellular fluorescence intensity dropped significantly
(Figure 8a), denoting the onset of the MPT. TDZD-8
successfully counteracted the DCLF-elicited quenching of
TMRM, and this effect was similarly blunted in cells
expressing the mutant S9A-GSK3b (Figure 8a).
Calcium overload–induced mitochondrial swelling, as
measured by a decrease in spectrophotometric absor-
bance at 540 nm, was similarly used to detect the MPT
(Figure 8b and c). There was a negative correlation between
the reduction in absorbance at 540 nm and the number
of apoptotic or necrotic cells (Figure 8c). Mitochondria
that were isolated from cells treated with DCLF displayed
increased swelling, whereas treatment with TDZD-8 attenu-
ated this effect, which was similarly diminished in the
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Figure 5 | Effects of glycogen synthase kinase-3b (GSK3b)
inhibition on the viability of renal tubular epithelial cells
injured with 2-[(2,6-dichlorophenyl)amino]phenyl-acetate
(DCLF). (a) Viability of murine tubular epithelial (TKPT) cells
following treatment with different doses of DCLF (0, 100, 200, and
400mM) for 24 h. *Po0.05 vs. normal controls; n¼ 6. (b) Survival
rate of TKPT cells after treatment with 200 mM DCLF for different
times. *Po0.05 vs. the beginning; n¼ 6. (c) Survival rate of TKPT
cells pretreated with different doses of 4-benzyl-2-methyl-1,2,4-
thiadiazolidine-3,5-dione (TDZD-8; 0, 5, 10, and 20 mM) and then
treated with 200mM DCLF for 24 h. *Po0.05 vs. DCLF-treated cells;
n¼ 6. (d) Survival rate of TKPT cells expressing either empty
vector or S9A-GSK3b after treatment with 200 mM DCLF, 10 mM
TDZD-8, or combined treatment. Ctrl, control; D, DCLF 200 mM; EV,
empty vector–transfected TKPT cells; S9A, S9A-GSK3b-transfected
TKPT cells; T, TDZD-8 10 mM. *Po0.05 vs. control cells; #Po0.05 vs.
the value of empty vector–transfected cells treated with DCLF.
Treatment with DCLF markedly decreased cell viability in a time-
and dose-dependent manner, whereas treatment with TDZD-8
improved survival rates (Po0.05). In contrast, the supportive
effect of TDZD-8 was blunted in cells transfected with vectors
carrying S9A-GSK3b, a mutant of GSK3b that is unable to be
phosphorylated at serine 9.
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Figure 6 | Effect of glycogen synthase kinase-3b (GSK3b)
inhibition on the apoptosis of murine tubular epithelial
(TKPT) cells treated with 2-[(2,6-dichlorophenyl)amino]
phenyl-acetate (DCLF). (a) TKPT cells were treated as indicated,
fixed, and exposed to TdT-mediated dUTP nick-end labeling
(TUNEL) to assess apoptosis. (b) Quantitative assessment of cell
apoptosis. Cells in a  200 field were manually counted in 10
fields per slide, with three replicates. Ctrl, control; D, DCLF 200 mM;
EV, empty vector–transfected TKPT cells; S9A, S9A-GSK3b-
transfected TKPT cells; T, 4-benzyl-2-methyl-1,2,4-thiadiazolidine-
3,5-dione (TDZD-8) 10mM. *Po0.05 vs. control cells; #Po0.05 vs.
empty vector–transfected cells treated with DCLF; n¼ 6. There
was a significant increase in the number of apoptotic cells
following exposure to DCLF vs. controls after 24 h (Po0.05).
The number of apoptotic cells was decreased to approximately
five per field in cultures pretreated with TDZD-8, whereas the
anti-apoptotic effect of TDZD-8 was attenuated in cells expressing
S9A-GSK3b.
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mitochondria of cells expressing S9A-GSK3b (Figure 8b).
All of these observations imply that the inhibition of GSK3b
protects tubular cells from apoptosis and necrosis by
inhibiting MPT pore opening in vitro.
GSK3b inhibition prevents DCLF-induced ATP reduction in
renal tubular epithelial cells
MPT pore opening allows the reentry of protons, thus by-
passing adenosine triphosphate (ATP) synthase and prevent-
ing the generation of ATP by the mitochondria. Consistent
with induction of the MPT, intracellular ATP levels were
drastically diminished in DCLF-treated TKPT cells (Figure 9).
Treatment with TDZD-8 retained intracellular ATP levels,
whereas this effect was not apparent in cells expressing S9A-
GSK3b, implying that the inhibition of GSK3b protects
tubular cells from death by preserving intracellular ATP
in vitro.
DCLF enhances the activity of redox-sensitive GSK3b in TKPT
cells
Upon exposure to DCLF, the production of reactive oxygen
species (ROS) was significantly increased, concomitant with
increased GSK3b kinase activity and diminished inhi-
bitory phosphorylation of GSK3b (Figure 10a, c, and d),
which is consistent with previous findings that GSK3b is a
reduction-oxidation (redox)-sensitive kinase.13 Mitochondria
are a major source of ROS production, and two main sites of
O2
 and H2O2 generation in the inner mitochondrial mem-
brane have been identified: complex I and complex III.
To identify the source of ROS production in response to
DCLF stimulation, rotenone and stigmatellin, inhibitors for
respiratory complexes I and III, respectively, were applied.
Treatment with rotenone did not prevent the increase of ROS
production or enhance GSK3b activity, denoting that
complex I is not the main site of DCLF-increased ROS
production. Consistently, DCLF failed to produce a direct
effect on the activity of reduced nicotinamide adenine
dinucleotide (NADH) dehydrogenase (Figure 10b). In contrast,
treatment with stigmatellin significantly suppressed the pro-
duction of ROS and the activation of GSK3b (Figure 10a, c,
and d), suggesting that mitochondrial ROS formation,
particularly at respiratory chain complex III, is involved in
DCLF-enhanced activity of redox-sensitive GSK3b.
GSK3b inhibition prevents cyclophilin D phosphorylation
in the mitochondria of TKPT cells exposed to DCLF
To explore whether and how GSK3b directly regulates MPT,
the expression of GSK3b in the mitochondria of TKPT cells
was examined. Fluorescent immunocytochemistry indicated
that a significant amount of GSK3b staining colocalized with
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mitochondrial staining, in agreement with the specific,
subcellular distribution of GSK3b in the mitochondria
(Figure 11a). To corroborate the morphological findings,
immunoprecipitation was performed and revealed that
GSK3b coprecipitated with cyclophilin D (Figure 11b),
indicating that GSK3b physically interacts with cyclophilin
D—a component of the MPT pore complex.
To further explore the mechanism by which GSK3b
regulates cyclophilin D activation, the cyclophilin D amino-
acid sequence was analyzed. Residues Ser118 and Ser190 of
mitochondrial cyclophilin D reside in consensus motifs (SXXXS)
for phosphorylation by GSK3b. As shown in Figure 11c,
DCLF treatment significantly increased the phosphorylation
of cyclophilin D. Conversely, inhibition of GSK3b by TDZD-
8 suppressed the phosphorylation of cyclophilin D, whereas
this effect was diminished in cells transfected with S9A-
GSK3b. Together, these results suggest that GSK3b inhibition
stabilizes the MPT by suppressing cyclophilin D phosphor-
ylation in the mitochondria of TKPT cells exposed to DCLF.
DISCUSSION
NSAIDs are prescribed to millions worldwide for the treat-
ment of osteoarthritis, rheumatoid arthritis, and muscle
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concentration was measured using the luciferase method. Ctrl,
control; D, DCLF 200 mM; EV, empty vector–transfected cells; S9A,
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pain.14 In 2008 alone, over 107,000 NSAID-related toxicity
cases were reported, more than 14,000 cases of which
required treatment in health-care facilities. DCLF is one of
the most frequently prescribed NSAID. A literature search on
DCLF-induced renal toxicity in humans identified a number
of cases, most of them associated with acute renal failure and
some of which were fatal.1,2
Basal PGs maintain normal glomerular perfusion and
glomerular filtration rate. The inhibition of PG synthesis by
DCLF leads to renal ischemia, a decline in glomerular
hydraulic pressure, and acute renal failure. GSK3b, a consti-
tutively active protein kinase with an important regulatory
role in cell signaling, differentiation, gene expression, and
apoptosis, has been implicated in the pathogenesis of
multiple kidney diseases, both chronic and acute.15–19 In this
study, we found that the inhibition of GSK3b activity by
TDZD-8, a small-molecule inhibitor of GSK3b, ameliorated
DCLF-induced AKI. This was associated with suppressed
GSK3b activity, induced inhibitory phosphorylation of
GSK3b, and increased COX-2 expression in the renal cortex.
Consistently, PGE2 concentrations in the renal cortex were
significantly elevated. Our finding is in agreement with
previous reports indicating that GSK3b inhibition may
induce COX-2 expression via the negative regulation of
extracellular signal-regulated kinases.20 Of note, the renal
protective effect of GSK3b inhibition by TDZD-8 was
blunted but still largely preserved in COX-2-null mice,
suggesting that GSK3b inhibition may attenuate renal injury
through mechanisms that are beyond COX-2 induction.
In addition to the induction of acute ischemic kidney
injury through the disturbance of PG homeostasis in the
kidney, treatment with DCLF can impinge on renal tubular
epithelial cells directly. Significantly, tubular cell mito-
chondria are a prime target of DCLF.4 We found that
mitochondria treated with DCLF were more likely to
undergo mitochondrial swelling induced by calcium and
were more susceptible to the shift of TMRM through the
opened pores. MPT, an increase in the permeability of the
mitochondrial membrane, is a common pathway leading to
cell death. DCLF-induced apoptosis and necrosis were
detected in vivo and in vitro, consistent with previous
reports.8,21 40OH-DCLF and 5OH-DCLF are the major urine
metabolites of DCLF in rodents and humans.22 DCLF, 40OH-
DCLF, and 5OH-DCLF induce concentration-dependent
apoptosis, and at equimolar concentrations the greatest
pro-apoptotic activity was produced by 5OH-DCLF.7
The MPT is under orchestrated regulation by a myriad of
cell signaling transducers, including GSK3b. Recent studies
have demonstrated that GSK3b inhibition has a central role
in the transduction of protective signals by raising the MPT
induction threshold.11,12,23 The phosphorylation of GSK3b at
serine 9 raised the MPT threshold and protected cells by
inhibiting the signaling cascades associated with the induc-
tion of the MPT.24,25 In this study, the inhibition of GSK3b
activity by TDZD-8 successfully prevented the swelling of
mitochondria that were isolated from DCLF-injured cells and
tissues, and this effect was attenuated in mitochondria from
cells expressing mutant GSK3b that is not able to be inhibited
via phosphorylation at serine 9, demonstrating that GSK3b
inhibition diminishes DCLF-triggered MPT pore opening.
Our findings are in agreement with a previous study by
Plotnikov et al.26 in which treatment with lithium ion, an
inhibitor of GSK3b, restored the mitochondrial membrane
potential in tubular cells from rat kidneys that were subjected
to ischemic reperfusion. In the present study, in murine
TKPT cells, DCLF induced a strong ROS burst and oxidative
stress. Although ROS can cause cell destruction by massive
lipid peroxidation, in most cases, ROS modulates signal
transduction pathways by affecting redox-sensitive enzymes,
organelles, and signaling transducers, such as GSK3b. Indeed,
the DCLF-elicited ROS burst was associated with the
enhanced activation of GSK3b, and both were abrogated by
treatment with stigmatellin but not rotenone. This suggests
that DCLF can interfere with the mitochondrial electron
transport chain, leading to augmented activation of the
redox-sensitive GSK3b kinase. Moreover, a significant sub-
cellular distribution of GSK3b was found to be colocalized
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Figure 10 | Effect of 2-[(2,6-dichlorophenyl)amino]phenyl-
acetate (DCLF) on reduction-oxidation (redox)-sensitive
glycogen synthase kinase-3b (GSK3b) in murine tubular
epithelial (TKPT) cells. TKPT cells were treated with 200 mM DCLF
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(a) Reactive oxygen species (ROS) formation was evaluated by the
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with the mitochondria, suggesting a potential regulatory role
for GSK3b in mitochondrial function. Thus far, the only MPT
components to be identified are the peripheral benzodiazepine
receptor, located in the mitochondrial outer membrane, and
cyclophilin D, localized to the matrix.27,28 Residues Ser118 and
Ser190 of mitochondrial cyclophilin D reside in GSK3b
phosphorylation consensus motifs. DCLF treatment signifi-
cantly increased the phosphorylation of cyclophilin D, which
may trigger the opening of the end-effector MPT pore.
Permeability of the mitochondrial inner membrane allows
solutes with a molecular weight ofo1500 Da to leak from the
mitochondria, and the subsequent breaking of mitochondrial
outer membrane leads to the release of proteins and cell
death.28,29 Conversely, inhibition of GSK3b successfully pre-
vented the phosphorylation of cyclophilin D in the mitochon-
dria, which may lead to the stabilization of the MPT.
Mitochondria have a crucial role in maintaining ATP-
dependent cellular processes.30 MPT pore opening allows the
massive reentry of protons into the mitochondrial matrix,
thus bypassing ATP synthase and preventing ATP synthesis.31
In this study, we observed a significant reduction in ATP
levels in DCLF-injured cells, consistent with the findings of
both Mingatto et al.5 and Ng et al.32 that DCLF depressed the
rate of ATP synthesis. The progression to necrotic or
apoptotic cell death depends, in part, on the effect of the
opening of the MPT pore on cellular ATP levels.33 If many
pores open, the major drop in cellular ATP levels triggers
cellular swelling and rupture of the plasma membrane, and
thus necrotic cell death ensues. If ATP levels are at least
partially maintained, the MPT is followed by apoptosis.
GSK3b inhibition has been shown to be a successful thera-
peutic strategy to prevent hepatic mitochondrial dysfunction
and improve the preservation of cellular ATP content
following ischemic reperfusion injury.34 In this study, we
observed that, following the inhibition of GSK3b by TDZD-
8, DCLF-elicited MPT was suppressed and intracellular ATP
levels were restored, leading to reduced tubular cell death.
In conclusion, TDZD-8, a highly selective inhibitor of
GSK3b, attenuates DCLF-induced AKI, suppresses tubular
cell death, and improves kidney function by inducing renal
cortical COX-2 expression and by inhibiting MPT in a
DCLF-induced nephrotoxicity model (Figure 12). Our
findings suggest that the inhibition of GSK3b by either novel
selective small-molecule inhibitors or existing FDA (Food
and Drug Administration)-approved drugs with GSK3b inhi-
bitory activity, such as lithium and valproate, represents a
novel therapeutic strategy for AKI, particularly for NSAID-
induced AKI.
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MATERIALS AND METHODS
Animal experimental design
Animal experimental studies were approved by the institution’s
Animal Care and Use Committee and they conform to the
USDA (United States Department of Agriculture) regulations and
the NIH (National Institutes of Health) guidelines for humane
care and use of laboratory animals. Drugs were given as previously
described.8,35 BALB/c mice aged 6–8 weeks were randomly
assigned to one of the five groups, and killed 24 h after DCLF
administration:
Group C (n¼ 6), control mice received vehicle alone;
Group T (n¼ 6), mice were only treated with selective GSK3b
inhibitor TDZD-8 (5mg/kg, intravenous, dissolved in 10% dimethyl
sulfoxide);
Group D (n¼ 6), mice were subjected to DCLF (200mg/kg)
injury by oral gavage and vehicle was given 1 h before DCLF injury;
Group TLþD (n¼ 6), mice were subjected to DCLF
(200mg/kg) injury by oral gavage. Low-dose TDZD-8 (1mg/kg,
intravenous, dissolved in 10% dimethyl sulfoxide) was given 1 h
before DCLF injury; and
Group TþD (n¼ 6), mice were subjected to DCLF (200mg/kg)
injury by oral gavage. TDZD-8 (5mg/kg, intravenous, dissolved in
10% dimethyl sulfoxide) was given 1 h before DCLF injury.
Congenic COX-2-knockout mice on a BALB/c background
were bred by backcrossing the COX-2-knockout mice on a mixed
129/C57 background, which were originally obtained from the
Jackson Laboratory (Bar Harbor, ME), with the inbred BALB/c mice
for more than 10 generations. Congenic homozygous COX-2-null
mice were bred by brother/sister mating of heterozygous animals of
the tenth generation. Genotyping was performed as previously
described.36
Renal pathology
Kidney sections were prepared and stained as previously described.37
Acute tubular injury was accessed using semiquantitative measure-
ments according to the proportion relative to the total section
area and classified as follows: 0 (nil), 1 (o25%), 2 (25–50%),
3 (50–75%), and 4 (475% of tubules).
Western immunoblot analysis and immunoprecipitation
Western immunoblot analysis was performed as previously de-
scribed.15 The antibodies against GSK3b, p-GSK3b, COX-1, and
COX-2 were purchased from Santa Cruz Biotechnology (Santa Cruz,
CA). For detection of phosphorylated cyclophilin D, cyclophilin D
antibody (Santa Cruz Biotechnology) was used as the immuno-
precipitation antibody and the antibody against phosphorylated
serine (Santa Cruz Biotechnology) was used to probe the immuno-
precipitation products by immunoblot analysis.
Measurement of PGE2 in kidney cortex
The PGE2 was measured using an enzymatic immunoassay kit from
Cayman Chemical (Ann Arbor, MI) according to the manufacturer’s
instruction.
Reverse transcription-PCR
Reverse transcription-PCR was performed as previously described
using specific primers (COX-2 sense, 50-GTGGAAAAACCTCGTCC
AGA-30, COX-2 antisense, 50-TGATGGTGGCTGTTTTGGTA-30).38
Cell culture and plasmid transfection
TKPT cells were grown in Dulbecco’s modified Eagle’s medium/F12
that contained 5% fetal bovine serum. The eukaryotic expression
vectors encoding the uninhibitable mutant (S9A-GSK3b-HA/
pcDNA3) were provided by Dr Johnson (Birmingham, AL),39 and
were transfected as previously described.15 Immunofluorescent
staining revealed that475% of the cells expressed the hemagglutinin-
tagged constructs 24 h after transfection. Cells were then subjected to
different treatments and assessed by MTT viability assay.40
Measurement of cell apoptosis
TUNEL staining was performed on fixed tissue sections or cell
cultures with a cell apoptosis detection kit (Roche Applied Science,
Indianapolis, IN) according to the manufacturer’s instructions.
Measurement of cell necrosis
Necrotic cell death was assessed by the propidium iodide exclusion
assay and lactate dehydrogenase release in the medium as previously
described.41
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Figure 12 |Glycogen synthase kinase-3b (GSK3b) inhibition
prevents nonsteroidal anti-inflammatory drug (NSAID)-
induced acute kidney injury by dual mechanisms.
Overinhibition of prostaglandin (PG) synthesis by NSAIDs leads to
renal ischemia, a decline in glomerular hydraulic pressure, and
acute renal failure. The 2-[(2,6-dichlorophenyl)amino]phenyl-
acetate (DCLF) is also able to injure renal tubular epithelial cells
directly by triggering reactive oxygen species (ROS) production,
enhancing the activity of reduction-oxidation (redox)-sensitive
GSK3b, and thereby promoting cyclophilin D phosphorylation and
the ensuing mitochondrial membrane permeability transition
(MPT) pore opening. GSK3b inhibition prevents NSAID-induced
acute kidney injury via both the induction of cortical
cyclooxygenase-2 (COX-2) and the inhibition of the MPT.
AKI, acute kidney injury; CyP-D, cyclophilin D.
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MPT assay
Mitochondria were isolated from kidney cells as previously
described.4,42 The protein concentration was determined with
bovine serum albumin as the standard. Mitochondrial swelling
was estimated on the basis of the decrease in the absorbance of
mitochondria (1.0mg protein) at 540 nm in 1ml of a medium
containing 125mmol/l sucrose, 65mmol/l KCl, 5mmol/l succinate,
5 mM rotenone, 20 mM CaCl2, and 10mmol/l Hepes-KOH, pH 7.2,
at 30 1C.
Fluorescent analysis of MPT
MPT pore opening in cultured cells was assessed using TMRM
(Sigma, St Louis, MO, USA). In brief, after different treatments,
TMRM (100 nM) was added to the culture and incubated at 37 1C
for 15min.43 Results were interpreted using fluorescence microscopy.
ATP assay
ATP content in cells was measured by the luciferase method in
freshly prepared cellular lysates using the ATP bioluminescence assay
kit provided by Roche Applied Science according to the manufac-
turer’s instructions.
Measurement of NADH dehydrogenase activity
The rotenone-sensitive reduction of decylubiquinone was measured
following the procedure reported for respiratory complex I activity
using a freeze–thawed mitochondrial extract (containing 0.3mg
protein).32 NADH fluorescence intensity was monitored at the
excitation/emission of 352/464 nm in the absence or presence of
200mM DCLF or 1 mM rotenone, which served as a positive control.
ROS production assay
ROS production in isolated cells was measured using 20,70-dichloro-
dihydrofluorescein diacetate as previously described.44
GSK3b kinase activity assay
GSK3b kinase activity was determined using an assay kit
commercially available from Sigma according to the manufacturer’s
instructions.
Fluorescent immunocytochemistry
TKPT cells were stained with MitoTracker Green FM (150 nM,
Molecular Probes, Carlsbad, CA) for 20min, and then fixed with 4%
paraformaldehyde and counterstained with anti-GSK3b antibodies
as previously described.45
Statistical analyses
For immunoblot analysis, bands were scanned and the integrated
pixel density was determined using a densitometer and an NIH
image analysis program (ImageJ, NIH, Bethesda, MD). All data are
expressed as mean±s.d. Statistical analysis of the data from multiple
groups was performed by one-way analysis of variance followed by
the Student–Newman–Kuels test. Data from two groups were
compared using t-test. The Po0.05 was considered significant.
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